Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura

Cephalalgia. 2024 Mar;44(3):3331024241237247. doi: 10.1177/03331024241237247.


Background/hypothesis: Experimental provocation studies have yielded important insights in migraine pathophysiology. Levcromakalim has been previously shown to induce migraine-like attacks with and without aura. In this study, we aim to further explore the migraine aura-inducing potential of levcromakalim.

Methods: In a double-blind, randomized, placebo-controlled cross-over study, 27 adult participants with migraine with aura received intravenous infusions of levcromakalim and saline. Headache, aura and associated symptoms were evaluated for 24 hours following administration of the study drug. The primary endpoint was occurrence of migraine-like attacks with or without aura in the 24-hour observation period.

Results: Thirteen participants developed migraine-like attacks on the active day only (P = 0.0098), and four participants developed aura on the active day only (P = 0.68). The median time to onset of migraine-like headache was three hours, and the median time to onset of aura was 27.5 minutes.

Conclusion/interpretation: Our findings affirm the potent migraine-inducing effect of levcromakalim. We observed a lower induction-rate of migraine aura than previously reported. Further studies are warranted to identify predictors of migraine aura following levcromakalim. identifier: NCT04905654.

Keywords: Headache; experimental study; migraine.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cromakalim
  • Cross-Over Studies
  • Double-Blind Method
  • Epilepsy*
  • Headache
  • Humans
  • Migraine Disorders* / drug therapy
  • Migraine with Aura*


  • Cromakalim

Associated data